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ABSTRACT 
 
Characterization of the Mitochondrial DNA Polymerase in Plasmodium falciparum 
Emily C. Reesey 
Dr. Akhil B. Vaidya 
 
 
 
Several anti-malarials in clinical use and under development act on the 
mitochondrial electron transport chain (mtETC) of malaria parasites.  The mtETC 
is an essential process requiring three proteins encoded by the mitochondrial DNA 
(mtDNA): cytochrome c oxidase subunits 1 and 3, and cytochrome b.  The 
mitochondrion of P. falciparum relies on nuclearly encoded machinery for the 
replication, transcription and translation of the mtDNA.  A candidate nuclear gene 
encoding mitochondrial DNA polymerase (mtDNAP) has been identified in P. 
falciparum.  However, to our knowledge this gene has not been characterized.  
Due to the essentiality of the P. falciparum mtETC as demonstrated by previous 
studies, mtDNAP is assumed to be essential for parasite survival.  Using single 
crossover homologous recombination, we have derived transgenic blood stage 
parasites with their endogenous mtDNAP locus tagged with TetR-DOZI aptamers.  
These transgenic parasites were used for conditional knockdown studies, 
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demonstrating a successful knockdown of mtDNAP.  Surprisingly, this was not 
accompanied by any change in parasite growth.  Further analysis of the mtDNA 
from knockdown parasites revealed a decreased amount of mtDNA, consistent 
with at least partial knockdown of the mtDNAP.  This study demonstrates that P. 
falciparum parasites can survive with a significantly decreased mtDNA, allowing 
opportunity for future studies.
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Chapter 1: Introduction to Malaria & the 
Mitochondria of Plasmodium falciparum 
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Malaria 
Malaria continues to be a global burden that is increasingly difficult to treat 
due to the development of drug resistant parasites to all current treatments (1).  In 
2015, there were an estimated 429,000 deaths worldwide as a result of malaria, the 
majority of which were children under the age of five within Africa (2).  The 
incidence of malaria deaths have decreased 21% between 2010 and 2015, along 
with a global decrease in mortality by 29% (2).  This is primarily attributed to 
increased vector control in the form of insecticide-treated mosquito nets and 
indoor insecticide spraying to prevent transmission of malaria (2). 
Current drug interventions involving artemisinin-based combination therapies 
(ACTs) for uncomplicated malaria have proven very effective against the most 
virulent of human malaria causing parasites, Plasmodium falciparum (3, 4).  
Although the burden of malaria continues to diminish, newly emerging drug 
resistant parasites against ACTs and other treatments requires a continued effort 
to find new drug interventions against malaria parasites.  This effort is necessary to 
achieve global eradication of the disease.  Recent studies have demonstrated that 
the mitochondrion of P. falciparum is a promising target for new anti-malarial 
drugs, due to its divergence from host mitochondria and the essential nature of 
the three proteins encoded by the parasite mitochondrial DNA (mtDNA), which 
will be discussed in detail (5). 
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Life Cycle of Plasmodium falciparum  
Malaria in humans is caused by infection with apicomplexan parasites of 
the genus Plasmodium, which are transmitted by the bite of female Anopheles 
mosquitoes harboring the parasites, as male mosquitoes do not take blood meals 
(6).  Severe malaria is most commonly caused by P. falciparum, but the disease 
may also arise from infection with P. vivax and P. ovale, which can uniquely remain 
dormant in the liver for up to a year, leading to multiple relapses of disease (6).  In 
addition to these three species, human malaria is also caused by P. malariae and P. 
knowlesi.  All of these parasites undergo a complicated life cycle, alternating 
between infection of the mosquito vector and the human host (Figure 1.1) (6). 
Malaria infection by P. falciparum begins when an infected mosquito takes a 
blood meal from a human host, transmitting the disease by injecting sporozoites 
from the salivary glands during feeding.  Upon entry into the blood stream, 
sporozoites travel to the liver, where liver stage schizonts develop over the course 
of approximately one week within hepatocytes.  Mature schizonts rupture 
releasing merozoites, which infect erythrocytes, or red blood cells (RBCs).  This 
initiates the asexual blood stage of the P. falciparum life cycle, which occurs 
cyclically over the course of 48 hours.  Within the erythrocytes, merozoites 
develop into early trophozoites, or ring stage parasites, and then mature 
trophozoites differentiate into schizonts.  As in the liver stage, the schizonts 
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Figure 1.1: The life cycle of Plasmodium falciparum. The cycle begins with the bite 
of an infected mosquito, injecting the sporozoites into a human host.  The 
sporozoites migrate to the liver to invade hepatocytes and further develop into 
schizonts over approximately one week, which burst and to release thousands of 
merozoites.  These merozoites invade erythrocytes, beginning the asexual blood 
stage of infection.  The merozoites will develop over 48 hours into early trophozoites 
(rings), mature trophozoites, and then schizonts, which will burst releasing 
merozoites for reinvasion of erythrocytes.  Some trophozoites will develop into male 
and female gametocytes for sexual reproduction within the mosquito, if taken up 
during a blood meal.  The gametocytes will form a zygote in the gut of the mosquito, 
which further develops into a motile ookinete that migrates to the salivary glands of 
the mosquito for oocyst development.  The oocyst will burst, releasing sporozoites 
for reinfection should the mosquito bite a susceptible host. Republished with 
permission from (7). 
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rupture releasing 6 to 30 merozoites per schizont for reinvasion of erythrocytes, 
thus reinitiating the blood stage cycle (7).   
A portion of invading merozoites develop into male and female gametocytes, 
which when taken up by a female Anopheles mosquito during a blood meal, 
allowing sexual reproduction of the parasites to begin within the gut of the 
mosquito.  Zygotes develop into motile ookinetes, invade the midgut and form 
oocysts that rupture to release infectious sporozoites which migrate into the 
salivary glands.  When an infected mosquito take a blood meal from a susceptible 
host, infection will occur and the life cycle will begin again (8). 
 
Presentation of Disease 
Clinically, malaria caused by P. falciparum is characterized into either 
uncomplicated or severe cases, with an incubation period of approximately two 
weeks (9).  Early signs of uncomplicated malaria include an irregular fever, 
becoming more cyclic in pattern after one week, along with flu-like symptoms (10).  
Treatment for uncomplicated malaria typically includes ACTs, rapidly curing 
approximately 90% of cases (7).  Without immediate treatment, more severe and 
potentially fatal symptoms can develop (7).  Severe malaria consists of the same 
symptoms as uncomplicated malaria, and is classified as having one or more of the 
following complications including, severe anemia, cerebral malaria, respiratory 
failure and acute renal failure (10).  The preferred treatment for severe malaria is 
6 
 
  
 
artesunate, a derivative of artemisinin, due to its high efficacy and low cost 
compared to other anti-malarial drugs (7).   
The cyclic nature of the bursting of erythrocytes during the asexual blood 
stage causes anemia, as new erythrocytes are not replenished fast enough (9).  The 
synchronous rupture of erythrocytes releases parasite toxins and antigens, which 
stimulate T cells to produce pro-inflammatory cytokines, such as IFN-γ and TNF-α, 
resulting in a corresponding cyclic fever and chills characteristic of malaria (11).  
Upon repeated exposure to parasitic infections, individuals can begin to exhibit a 
low level of immunity as a result of malaria-specific antibodies and T-cells, causing 
less severe symptoms and quicker clearance of parasites (11, 12).  Alternatively, 
some individuals experience severe symptoms again due to cyclic cytokine 
production (12).   
Malaria parasites also exhibit great antigenic variation as a means to 
subverting the immune response, allowing infection to persist for an extended 
time (9).  Individuals with multiple exposures to parasitic infection are capable of 
developing natural immunity over a long period of time, likely producing multiple 
antibodies to a variety of epitopes presented by the parasites (7).  This level of 
protection has yet to be reproduced by a vaccine (7, 12). Antigenic diversity is the 
primary cause of drug resistant parasites, contributing to the increasing difficulty 
of treating malaria (12, 13).   
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Drug Resistance 
Unfortunately, resistance to artemisinin is an emerging problem throughout 
Southeast Asia, potentially undermining current strides in malaria treatment and 
prevention (14).  Prior to artemisinin, chloroquine and sulfadozine-pyrimethamine 
were the primary treatments of choice, with resistance to these drugs developing 
throughout Southeast Asia, spreading to India and Africa shortly after (Figure 1.2) 
(15).  Given this history of drug resistance, it is imperative that artemisinin 
resistance is closely monitored, which is now possible using the newly discovered 
kelch 13 mutation as a molecular marker in resistant parasites (15). 
In order to fully understand the development of artemisinin resistance in P. 
falciparum, studies were conducted on lab isolates from Tanzania (16).  Under 
artemisinin pressure eight mutations occurred across seven genes, with the most 
promising mutation located within chromosome 13, as this mutation has been 
frequently observed in other studies (16-18).  Further research determined that 
there were many non-synonymous single nucleotide polymorphisms located in the 
kelch propeller domain (kelch13), with these mutations identified in resistant 
parasite isolates from Cambodia as well (16).  Although it is not fully understood 
why the kelch13 mutations provide protection for the parasites, this mutation can 
now be used as a molecular marker to better monitor the spread and scale of 
artemisinin resistance (15). 
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Figure 1.2: Spread of chloroquine resistance from the Mekong region of Cambodia 
throughout Southeast Asia and Africa, with resistance also emerging in South 
America, from 1957 through 1990. Republished with permission from (19). 
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Anti-malarials, such as atovaquone and quinolones, act on the Q-cycle within 
complex III of the mitochondrial electron transport chain (mtETC) in malaria 
parasites and have been successful in treating the disease (5).  Like artemisinin, 
high levels of resistance to atovaquone and similar drugs targeting the ubiquinol 
oxidation site of cytochrome b have quickly emerged (20, 21).  To combat the 
growing resistance to atovaquone, addition of proguanil to drug treatments lowers 
the required dose of atovaquone for parasite clearance through a synergistic 
interaction, but once the resistance mutation at cytochrome b is developed by the 
parasites, the effect of both drugs are lost (5). The success of these drugs suggests 
the potential of additional drug targets against the parasite mitochondria, utilizing 
the evolutionary divergence from the host human mitochondria.  
 
Evolution of the Mitochondria 
 The mitochondria of most eukaryotes are commonly referred to as the 
powerhouse of the cell and are integral parts of metabolism.  Creation of the 
mitochondria occurred by an endosymbiotic event with alphaproteobacteria, thus 
forming eukaryotic cells (22).  Within the phylum Apicomplexa, including P. 
falciparum, mitochondria are long organelles with tubular cristae, allowing for 
optimal surface area within the organelle for metabolic reactions (23).  The main 
processes of the mitochondria are the tricarboxylic acid (TCA) cycle and mtETC.  
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Typically, the TCA cycle functions to oxidize acetyl-CoA through a series of 
reactions, producing CO2 and some ATP molecules, as well as electrons to fuel 
oxidative phosphorylation within the mtETC, the primary source of ATP 
production (24).  However, studies have demonstrated that blood stage P. 
falciparum parasites rely on ATP generation from the conversation of glucose to 
pyruvate during glycolysis, with the TCA cycle being non-essential for parasite 
survival (25).  This discovery also brings into question the purpose of the mtETC 
within the parasite, to be discussed in the following section. 
Although the mitochondria of eukaryotes are descendent of an 
alphaproteobacterium, the inherited genome of the mitochondria has evolved 
across alveolate species to be highly diverse, with Cryptosporidium species losing 
their mitochondrial genome completely (5).  The Alveolate clade contains three 
major groups including ciliates, dinoflagellates, and apicomplexans, all with great 
differences in the evolution of their mitochondrial genome. Ciliates have the 
largest mtDNA of all the groups at approximately 47kb, containing 45 open 
reading frames (ORFs), 20 of which are unique to the ciliates (26).  The 
dinoflagellates and apicomplexans have a much smaller mtDNA, each with only 
three ORFs, implying that the divergence of these groups occurred after significant 
loss of the mtDNA (5).  Differences between dinoflagellates and apicomplexans are 
observed in the arrangement of mtDNA, with the former encoding on multiple 
DNA molecules and the latter demonstrating DNA molecules arranged in head-to-
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tail tandemly repeated arrays (27, 28).  The ORFs of both groups encode for the 
same three proteins, cytochrome c oxidase subunits I and III and cytochrome b, all 
required for the electron transport chain (5). 
 
The Mitochondrial Electron Transport Chain 
 The mtETC is responsible for producing a transmembrane proton gradient 
across the inner membrane of the mitochondria through the reduction of oxygen 
to water (24).  This proton gradient fuels oxidative phosphorylation to produce 
ATP from ATP synthase, also known as complex V, the primary source of ATP in 
eukaryotic cells (24).  In addition to ATP synthase, eukaryotes have four complexes 
within the mitochondrial inner membrane that function to transfer electrons to a 
higher energy state and pump protons against the gradient of the inner membrane 
(29).  The complexes consist of NADH-ubiquinone oxidoreductase (complex I), 
succinate-ubiquinone oxidoreductase (complex II), ubiquinol-cytochrome c 
oxidoreductase (complex III), and cytochrome c oxidase (complex IV) (5).  
Complexes I, III, and IV function to pump protons against the gradient of the inner 
membrane into the inner membrane space, generating a protonmotive force, while 
complex II introduces electrons derived from succinate but does not function as a 
proton pump (30).  There are also two additional proteins, ubiquinone (Coenzyme 
Q) and cytochrome c, which shuttle electrons between the complexes (30).   
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As previously noted, P. falciparum in the asexual stages generates ATP 
through glycolysis due to the high availability of glucose (31).  Although these 
blood stage parasites do not use the mtETC to produce ATP, it is still essential for 
other processes, including maintenance of the membrane potential within the 
mitochondria and pyrimidine biosynthesis (29).  The mtETC of P. falciparum is 
similar to higher eukaryotes, and is generally more simplified with the loss of 
complex I, as seen in Figure 1.3 (29, 31).  Electron transfer between complexes II-
IV occurs as in higher eukaryotes but with less activity, the only exception being 
the loss of some subunits within the complexes, again demonstrating a simpler 
system (29).  Complex III, or cytochrome bc1 complex, of the P. falciparum mtETC 
is of particular interest, due to its susceptibility to inhibitors such as atovaquone, 
which bind the ubiquinol oxidation site (Qo) of the complex (32, 33).  By binding 
and blocking the Qo site, electrons cannot be transferred and ubiquinone is not 
reoxidized to ubiquinol (33). Atovaquone resistance is directly related to a 
mutation in cytochrome b at position 268, a tyrosine residue, altering the Qo site 
and preventing atovaquone, as well as other inhibitors, from functioning (33). 
 Five mitochondrial dehydrogenases within the mtETC of P. falciparum 
contribute to the Q cycle by reducing coenzyme Q (CoQ) and feeding electrons 
into the mtETC (31).  Specifically the dihydroorotate dehydrogenase (DHODH) has 
an additional role in pyrimidine biosynthesis, an essential pathway for survival as 
parasites cannot salvage pyrimidines (5).  DHODH catalyzes the conversion of  
13 
 
  
 
 
Figure 1.3: The mitochondrial electron transport chain of P. falciparum, including 
the five dehydrogenases of the Q cycle, complexes II-V, and cytochrome c. 
Republished with permission from (31). 
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dihydroorotate to orotate, the only redox reaction in the pyrimidine biosynthesis 
pathway (34).  A study by Painter et al. (35) expressed a class 1 yeast DHODH 
(yDHODH) in P. falciparum blood stage parasites, producing parasites resistant to 
complex III inhibitors, including atovaquone.  These transgenic parasites 
functioned completely independent of the mtETC, as yDHODH uses fumarate as 
an electron acceptor instead of CoQ, allowing pyrimidine biosynthesis to occur 
without reliance on the Q cycle.  Interestingly, transgenic yDHODH expressing 
parasites were susceptible to proguanil in combination with complex III inhibitors, 
indicating that the drug targets a function that is only essential without the 
mtETC.  Further study confirmed that proguanil in the presence of atovaquone 
disrupts the membrane potential of the mitochondria, leading to collapse of the 
membrane and parasite death.  This work demonstrates the essential nature of the 
mtETC, and questions if mtDNA responsible for encoding three of the required 
proteins for this process can be manipulated as well. 
 
The Mitochondrial DNA  
The mtDNA of P. falciparum is a total of 6 kb in length, the smallest 
mtDNA known within eukaryotes (36).  The mtDNA encodes only three genes, 
Cox1, Cox3 and Cytb, which produce the proteins cytochrome c oxidase subunits 1 
and 3, and cytochrome b, as stated previously, and the ribosomal RNA required to 
produce ribosomes for translation of these proteins (Figure 1.4) (5, 37).  The 
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transcription and translation of mtDNA requires nuclearly encoded machinery, 
transfer RNAs, and polymerases to be imported into the mitochondria after 
translation in the cytosol of the parasites (29).  All other proteins required for the 
mitochondria are also nuclear encoded and transported to the mitochondria after 
translation (29). 
There are approximately 30 copies of the mtDNA arranged in head-to-tail 
tandem arrays, with replication occurring in a unique mechanism not commonly 
seen in eukaryotes (38).  Initiation of mtDNA replication coincides with the start 
of nuclear replication at the late trophozoite stage during the asexual blood cycle 
(39).  Studies have confirmed that the replication of mtDNA occurs by a rolling 
circle mechanism, with multiple single stranded copies of the DNA produced in a 
head to tail arrangement called a concatemer (39).  This method of replication is 
thought to arise due to the complex aggregates formed from the intramolecular 
recombinational activity of linear concatemers within the mitochondria (39).  To 
further investigate the requirement of replicating these three genes, the 
mitochondrial RNA polymerase (mtRNAP) of P. falciparum has been studied as a 
possible anti-malarial drug target. 
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Figure 1.4:  The mitochondrial genome of P. falciparum.  The map depicts the 6kb 
mitochondrial DNA, with genes above the line transcribed left to right and genes 
below the line transcribed right to left.  This sequence is tandemly repeated to form 
the entire genome.  The genes cox1, cox3 and cob produce the proteins cytochrome 
c oxidase subunits 1 and 3, and cytochrome b, respectively.  Protein coding regions 
are indicated by white boxes, with small mitochondrial rDNA sequences for the 
large subunit (LSU) rRNAs shown in blue (rRNA fragments SA-SF) and the small 
subunit (SSU) rRNAs shown in green (rRNA fragments LA-LG).  Two tentative 
rRNAs (TENT) are shown in red, with the untranslated regions (UN) shown in black.  
Republished with permission from (37). 
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The Mitochondrial RNA Polymerase 
The mitochondrial RNA polymerase (mtRNAP) (PF3D7_1125300) of P. 
falciparum is a nuclearly encoded protein required for transcription of genes 
replicated from the mtDNA (40, 41).  Another proposed purpose of the mtRNAP is 
for generation of RNA primers to initiate replication of the mtDNA (40). A recent 
study by Ke et al. (41) demonstrated that mitochondrial RNA polymerase 
(mtRNAP) is essential in asexual blood stage parasites since gene knockout 
attempts were unsuccessful.  The goal of the study was to produce parasites 
lacking the mtDNA for further investigation of the functions of the mitochondria 
in parasites.  Knockouts were conducted in yDHODH-expressing parasites 
independent of the mtETC and should not require the mtRNAP, as proteins 
encoded from the mtDNA would no longer be necessary; however, the mtRNAP 
gene could not be knocked out. Due to the essential nature of mtRNAP in P. 
falciparum, another potential drug target could be the mitochondrial DNA 
polymerase (mtDNAP) (PF3D7_0625300), an enzyme that has yet to be well 
characterized.  
 
The Mitochondrial DNA Polymerase 
The mtDNAP in P. falciparum is a proposed γ-like polymerase with some 
homology to eukaryotic DNA polymerase γ, as both function to replicate the 
mitochondrial DNA (42).  A study by Petmitr et al. (42) previously investigated the 
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enzymatic activity of the mtDNAP by partially purifying it from isolated blood 
stage P. falciparum mitochondria using fast protein liquid chromatography (FPLC).  
The polymerase was characterized to be mitochondrial based on resistance and 
susceptibility to known DNA polymerase inhibitors, as different DNA polymerase 
types have varying susceptibilities (43).  DNA polymerases in eukaryotes can be 
classified into two categories, aphidicolin-sensitive and aphidicolin-resistant, the 
latter of which only includes DNA polymerase β and γ (43).  Of those two DNA 
polymerases, β is resistant to N-ethylmaleimide while γ is susceptible, and this 
difference was utilized to classify the purified polymerase.  The purified enzyme 
showed resistance to aphidicolin and susceptibility to N-ethylmaleimide, both of 
which have been observed in eukaryotic DNA polymerase γ, confirming that it is a 
γ-like DNA polymerase.  The polymerase activity of the purified mtDNAP was 
analyzed using activated calf thymus DNA as a template to quantify enzyme 
activity, and polymerase activity was observed in the presence of aphidicolin.  This 
study characterized the enzymatic profile of the mtDNAP, but requires further 
investigation to confirm that the polymerase primarily functions in the 
mitochondria.   
 
Specific Aims 
Until recently, there was little to no information on the genomic sequence of P. 
falciparum DNA polymerases of any type, limiting further research.  Since the 
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study by Petmitr et al., the P. falciparum genome sequencing project determined 
the putative genomic sequence of mtDNAP, along with many other genes, and it 
can now be utilized to further study and manipulate the enzyme (44).  With 
confirmation of the presence of a DNA polymerase in the P. falciparum 
mitochondria by Petmitr et al., studies can be completed on the genomic level in 
order to determine the essentiality of the protein.  Based on the study by Ke et al., 
it is likely that the mtDNAP will exhibit similar properties as the mtRNAP, since 
the mtRNAP is essential for transcription of messenger RNA (mRNA) from 
replicated mtDNA by the mtDNAP.  The mRNA is most likely necessary for 
production of proteins required outside of the mitochondria, because otherwise 
the mtRNAP would have been able to be disrupted.  Given this information, we 
hypothesized that the mitochondrial DNA polymerase is essential for parasite 
survival due to the requirement of the mitochondrial DNA polymerase for 
replication of mtDNA in P. falciparum parasites.  The specific aim of this thesis is 
to determine whether mitochondrial DNA polymerase is essential for the survival 
of blood stage P. falciparum by using a conditional knockdown system and growth 
assay analysis. 
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Plasmid Construction for Knockdown of mtDNAP 
The pMG75/TetR-DOZI plasmid from Ganesan et al. (45) was modified for 
knockdown of P. falciparum mtDNAP.  The PfATP4 gene was removed from the 
pMG75 plasmid by restriction digest using specific restriction endonucleases (New 
England Biolabs) for the AflII (5’) and BstEII (3’) sites flanking the insert.  A 1031 
bp homology region at the 3’ end of the mtDNAP (PF3D7_0625300) gene, 
immediately before the stop codon, was isolated by polymerase chain reaction 
(PCR) from wild type (WT) D10 parasite genomic DNA (gDNA) using gene specific 
primers listed in Table 2.1.  Primers were designed with the same restriction sites 
used to remove PfATP4 from the plasmid.  The mtDNAP insert was purified and 
digested with the same enzymes used on the plasmid and cloned into the 
linearized pMG75 plasmid, producing the final construct (Figure 2.1).  The 
construct was transformed into competent cells, with kanamycin resistance for 
positive selection, and colonies were screened by PCR to confirm transformation of 
the full vector construct.  Positive colonies with the full construct were verified by 
sequencing (Genewiz) and restriction digest.  A single positive clone was grown in 
bacterial culture and a maxi prep kit (Qiagen) was used to isolate and purify the 
plasmid DNA.  The pMG75/mtDNAP vector DNA was precipitated into sterile 
50µg aliquots for parasite transfection.  Blasticidin (BSD) resistance was used as 
the selectable marker for transgenic parasites in culture, with presence of 
anhydrotetracycline (aTc) to prevent premature knockdown of mtDNAP. 
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Plasmid Construction for Knockout of mtDNAP 
 The pUF-1 plasmid with the mtDNAP 5’ and 3’ homology regions was made 
previously by Suresh Ganesan and Hangjun Ke (Figure 2.2).  In brief, the 5’ 
homology region (5’HR) was cloned into the pUF-1 plasmid using specific primers 
(Table 2.1) with the NcoI and EcoRI restriction sites.  The 3’ homology region 
(3’HR) was cloned into the plasmid using specific primers (Table 2.1) with the 
SacII and SpeI restriction sites.  Guide RNAs (gRNAs) between the 5’HR and the 
3’HR were designed using the Eukaryotic Pathogen CRISPR guide RNA Design 
Tool (http://grna.ctegd.uga.edu/) developed by the University of Georgia to find 
specific PAM sites within the sequence (Table 2.1).  These guides were ligated into 
the Cas2A plasmid by infusion.  Cloning and preparation for transfection of the 
pUF-1 construct and Cas2A constructs occurred as previously stated, with 
ampicillin resistance used for positive selection.  The plasmid contains yDHODH 
to generate DSM1 resistance as the selectable marker for transgenic parasites in 
culture. 
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Cloning Region Primer Name Sequence 
mtDNAP forward 
insert (pMG75) 
DNAPolI_F ATCTTAAGCAACTAATAATGTATCAACCAATA
ATG 
mtDNAP reverse 
insert (pMG75) 
DNAPolI_R TAGGTAACCATTGAAGACTCCTTGTAGACTCC 
mtDNAP 5’HR 
forward (pUF-1) 
5pDNApolsen_F CTCCATGGAAGATGCAGATGAACATACAGATC 
mtDNAP 5’HR 
reverse (pUF-1) 
5pDNApolasen_R GTGAATTCGATAATCTTCCTGTTGATGCTCC 
mtDNAP 3’HR 
forward (pUF-1) 
3pDNApolsen_F CAACTAGTGAAAGTGAACATGATGCTACC 
mtDNAP 3’HR 
reverse (pUF-1) 
3pDNApolasen_R TACCGCGGTCGTGTATACTTTAATTTGCATCC
TC 
mtDNAP gRNA 1 
forward (pUF-1) 
DNAp1_gRNA1_F CATATTAAGTATATAATATTCACCTTCGATTAT
AAACAAAGTTTTAGAGCTAGAAATAGC 
mtDNAP gRNA 1 
reverse (pUF-1) 
DNAp1_gRNA1_R GCTATTTCTAGCTCTAAAACTTTGTTTATAATC
GAAGGTGAATATTATATACTTAATATG 
mtDNAP gRNA 2 
forward (pUF-1) 
DNAp1_gRNA2_F CATATTAAGTATATAATATTTTATATGGACAA
ACTGAAAAGTTTTAGAGCTAGAAATAGC 
mtDNAP gRNA 2 
reverse (pUF-1) 
DNAp1_gRNA2_R GCTATTTCTAGCTCTAAAACTTTTCAGTTTGTC
CATATAAAATATTATATACTTAATATG 
mtDNAP gRNA 3 
forward (pUF-1) 
DNAp1_gRNA3_F CATATTAAGTATATAATATTTCTGCTGCACAT
CCTTGTATGTTTTAGAGCTAGAAATAGC 
mtDNAP gRNA 3 
reverse (pUF-1) 
DNAp1_gRNA3_R GCTATTTCTAGCTCTAAAACATACAAGGATGT
GCAGCAGAAATATTATATACTTAATATG 
Table 2.1: Primer sequences for vector cloning. Primers used for cloning of the 
mtDNAP homology regions into the pMG75 plasmid and pUF-1 plasmid, and for 
cloning the guide RNAs into the Cas2A plasmid. 
 
Cloning Region Primer Name Sequence 
mtDNAP forward 
integration check 
mtDNAP_Intg_F AATCAAATTGGAGCATCAACA 
mtDNAP reverse 
integration check 
DNAp1_2Xchk_R CCTTCATTTATCATCATCATC 
Aptamer reverse 
check 
3’_TetR_Check ATATTTCATGTCTCAGTAAAGTCTTTCAATAC 
mtDNAP reverse 
3’UTR flanking  
mtDNAP3f_R ATGACGTCGAAAAGTATTAATGATGATCTG 
Table 2.2: Primers for PCR of pMG75 transgenic parasites. Primers used to check 
for vector integration, wild type parasites, and aptamer length, with the same 
forward primer for each reaction. 
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Figure 2.1: pMG75/TetR mtDNAP vector construct for single crossover 
recombination of plasmid into the 3’UTR after the mtDNAP gene. 
 
 
 
Figure 2.2: pUF-1 mtDNAP vector construct for double crossover recombination of 
plasmid at the 3’ end of the mtDNAP gene after cutting by Cas9. 
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Parasite Culture & Transfection 
The D10 strain of Plasmodium falciparum cultured in human O+ 
erythrocytes at 5% hematocrit in RPMI 1640 media was the primary wild type 
strain used for transfections, with some transfections in NF54.  RMPI 1640 
medium was supplemented with 10mg/L 3H-hypoxanthine (Sigma), 15mM HEPES 
(Hyclone), NAHCO3 (Cellgro), 0.5% Albumax II (InVitrogen), and 50µg/mL 
gentamycin (Cellgro).  Parasites were incubated at 37˚C, with a gas mixture of 6% 
O2, 5% CO2 and 89% N2.  Ring stage parasites were transfected by electroporation 
at approximately 5-7% parasitemia using 0.2cm cuvettes, with 250µL parasitized 
erythrocytes and 50µg of plasmid DNA in cytomix solution.  Electroporation 
occurred at 0.31Kv and 960µFD, and parasites were transferred to a T25 vented 
flask with an additional 0.2mL of 50% RBCs and 9mL RPMI media.  Drug selection 
media was added two days after transfection and parasites were maintained until a 
stable population recovered from electroporation. 
 
Drug Cycling to Generate Integrated Transgenic Parasites 
 Once parasites recovered from transfection, integration of pMG75/TetR 
vector DNA into the parasite genome was confirmed by PCR analysis with flanking 
primers listed in Table 2.2.  Presence of wild type resistant parasites and length of 
aptamer was also confirmed using specific primers (Table 2.2).  Parasites were 
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isolated from red blood cells using saponin lysis (0.01% final concentration) and 
DNA was purified using the QIAamp DNA Blood Mini kit (Qiagen).  Parasites 
without integration were drug cycled by maintaining BSD drug pressure for three 
weeks, followed by removal of BSD from the RPMI media for four weeks.  Drug 
pressure is again added for an additional week, and DNA was collected from 
parasites to check for integration by PCR analysis. 
 
Parasite Cloning by Limiting Dilution 
 Mixed parasite culture of transgenic parasites and resistant wild type 
parasites were cloned by limiting dilution as described previously by Ke et al. (25).  
Briefly, the culture was diluted to a 1:10 stock, and the erythrocyte cell density was 
determined using a hemocytometer.  Parasitized erythrocytes per mL was 
determined by multiplying the cell density by the parasitemia.  The 1:10 stock was 
diluted to final concentrations of 2.5 and 0.5 parasitized RBCs per mL, and plated 
into separate 96 well plates to provide an average of 0.5 and 0.1 parasitized RBC 
per well.  Plates were maintained with regular feeding and a 1:2 split at day 10 and 
day 17.  Once a parasite population was established, parasite clones were expanded 
to larger cultures and screened by PCR for transgenic and wild type parasites.  
Pure transgenic parasite clones were also checked for length of aptamer. 
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Immunofluorescence Assay 
Transgenic parasites with Myc-tagged mtDNAP from the pMG75 plasmid 
are maintained in RPMI media at 5% hematocrit containing BSD and aTc.  
Parasites were prepared for immunofluorescent analysis as previously described by 
Tonkin et al. (46).  Briefly, at 5-7% parasitemia, a 1mL sample was collected and 
treated with 60nM MitotrackerRed for mitochondrial staining.  Cells were fixed 
with 4% formaldehyde and 0.0075% glutaraldehyde overnight at 4˚C, then 
permeabilized with 0.1% TritonX100 in PBS for 10 minutes, followed by 3X PBS 
washes.  Cells were treated with 0.1mg/mL sodium borohydride in PBS for 10 
minutes and then blocked with 5% BSA overnight at 4˚C.  Blocked cells were 
treated with rabbit polyclonal Myc antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and then anti-rabbit AlexaFluor488 fluorescent antibody 
(Molecular Probes, Eugene, Oregon, USA), both at a 1:300 dilution in 1% BSA in 
PBS overnight at 4˚C, with 3X PBS washes between antibodies.  Slides are prepared 
by treating stained samples with antifade and fluoromount for imaging on an 
Olympus BX60 epi-fluorescence microscope system. 
 
Knockdown Assay 
 Ring stage D10 transgenic parasites were tightly synchronized using alanine 
and grown to 7-10% parasitemia.  At the trophozoite stage, parasites were washed 
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3X with RPMI media and split 1:10 into fresh blood to remove excess aTc from the 
culture.  Cultures were established in T75 flasks with 3mL total blood and were 
maintained RPMI/BSD media with or without aTc for 20 days, or 10 cycles.  Every 
24 hours, a smear slide was prepared and 50µL of parasitized RBCs (25µL packed) 
was collected for flow cytometry analysis from each flask.  Every 48 hours, 
parasites were isolated by saponin lysis (0.01% final concentration) with ¼ of the 
flask collected for PCR analysis and ½ of the flask for Western blot analysis.  
Parasite pellets collected from the saponin lysis were stored at -20˚C until 
prepared for analysis.  The remaining ¼ of the flasks were replenished with fresh 
blood to a final volume of 3mL RBCs.   
 
Western Blot Analysis to Confirm Knockdown 
 Parasite pellets collected during the knockdown assay were resuspended to 
5-10X volume of the pellet using 50mM Tris-HCl pH 6.8 and 2% SDS buffer.  
Samples were prepared using 20µL of the resuspended pellet, 8µL of 4X SDS 
loading buffer and 3µL of 5% β-mercaptoethanol.  The parasite lysates were heated 
for 10 minutes at 85˚C and then centrifuged for 5 minutes at 14,000 RPMs.  The 
samples were loaded onto a 4-15% gradient pre-cast SDS-PAGE gel (Bio-Rad 
Laboratories, USA) at 100V for 1.5 hours and transferred onto a polyvinylidene 
difluoride membrane activated with methanol at 100V for 1 hour.  Membranes 
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were blocked in 10% non-fat milk in TBS-0.1% Tween for one hour.  The 
membrane was probed with a 1:8000 dilution of rabbit polyclonal Myc antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) in 1% non-fat milk in TBS-0.1% 
Tween overnight at 4˚C.  The membrane was washed 3X in TBS-0.1% Tween and 
probed with a 1:8000 dilution of goat anti-rabbit-IgG HRP (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) in 1% non-fat milk in TBS-0.1% Tween 
overnight at 4˚C.  The membrane was washed 3X in TBS-0.1% Tween and 
developed by autoradiography using the SuperSignal West Femto 
Chemiluminescent Maximum Sensitivity substrate (Thermo Scientific, Rockfield, 
IL, USA) at a 1:2 dilution in PBS for 5 minutes.  The membrane was washed as 
above and then probed with HRP conjugated rabbit polyclonal Plasmodium 
Aldolase antibody (Abcam, Cambridge, MA, USA) at a 1:10,000 dilution as a 
loading control.  The membrane was washed and developed by autoradiography 
using the SuperSignal West Pico Chemiluminescent substrate (Thermo Scientific, 
Rockfield, IL, USA) for 5 minutes. 
 
Growth Assay by Flow Cytometry 
 Parasite samples collected for flow cytometry were washed 3X in PBS and 
fixed in 4% formaldehyde and 0.0075% glutaraldehyde overnight at 4˚C.  Samples 
were stored at 4˚C until prepared for staining.  Fixed samples were washed 3X with 
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PBS and stained nucleic acid content with 1mM SYBR Green (Thermo Scientific, 
Rockfield, IL, USA) for 90 minutes while rotating.  The stain was removed by again 
washing 3X with PBS.  Stained samples were analyzed using the Accuri C6 flow 
cytometer (BD Biosciences, San Jose, CA, USA) on the FL1 channel for SYBR Green 
signal.  Parasites were gated using unstained and stained RBCs as controls, with a 
signal intensity above approximately 105 fluorescent units indicating parasitized 
RBCs. 
 
Quantitative PCR Analysis of mtDNA 
 Genomic DNA (gDNA) was purified from the parasite pellets collected 
during the knockdown assay using the QIAamp DNA Blood Mini kit (Qiagen).  
Total volume for each PCR reactions was 20μL with the following conditions: 10μL 
SYBR Green (Applied Biosystems, Warrington, UK), 1μL forward primer (10μM), 
1μL reverse primer (10μM), 50ng gDNA based on sample concentration and H2O 
up to 20μL.  Primers used for quantitative PCR (qPCR) are listed in Table 2.3, with 
cytochrome b used to determine the presence of mtDNA and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) used as a control gene.  PCR reactions were 
plated in triplicate, with D10 WT gDNA and samples without gDNA used as 
controls.  .  To determine the fold change of the amount of mtDNA, the average for 
each sample was determined from the technical replicates.  The D10 Ct mean was 
then subtracted from the Ct means of the samples for each gene, to determine the 
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ΔCt value for each sample.  The GAPDH ΔCt for each sample was subtracted from 
the corresponding cytrochrome b ΔCt, to give the ΔΔCt for each sample. Then, the 
following formula was used to calculate the final fold change: (-ΔΔCt)2.  The fold 
changes were normalized to samples with aTc for each time point and plotted 
accordingly. 
 
Growth Inhibition Assays 
 Growth inhibition assays were conducted as described in Desjardin et al. 
(47).  Briefly, the parasite cultures were plated in 96 well plates at approximately 
1.0% parasitemia in 3% hematocrit.  Serial dilutions of specific drugs and inhibitors 
were added in the presence or absence of aTc and then pulsed with 0.5μCi of 3H-
hypoxanthine for 24 hours.  The plates were frozen at -80˚C for 24 hours, then 
thawed to 37˚C to lyse the parasites and harvested onto EasyTabTM-C Self-
aligning glass fiber filters (Packard, Meridian, CT, USA), followed by multiple 
washes.  The filters are dried and placed into an OmnifilterTM 96-well plate filter 
case (Packard, Meridian, CT, USA).  To measure the beta-radiation of 3H-
hypoxanthine incorporation, 30μL OmniScintTM (Packard, Meridian, CT, USA) 
scintillation fluid is added to the wells.  A TopCountTM radiation counter is used 
measure cell proliferation by the counts per million (cpm) of radioactivity 
incorporation into the nucleic acids.  The cpm is used to determine the percent 
growth, and then plotted to determine the best fit curve and the IC50 of each drug. 
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Cloning Region Primer Name Sequence 
Cytochrome b 
forward 
Cytochromeb_F AGCAAGTCGATATACACCAGATG 
Cytochrome b 
reverse 
Cytochromeb_R ACCTGTTGCGTGCATGTATC 
GAPDH forward rGAPDHPfF TCCTTGGGGAAAATGCCAAGT 
GAPDH reverse rGAPDHPfR TGGGGTGTCATCCTTTGGTG 
Table 2.3: Primers for qPCR analysis.  Cytochrome b primers generate a product of 
106bp used to quantify the amount of mtDNA.  GAPDH primers generate a product 
of 136bp used as a housekeeping gene control. 
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Chapter 3: Characterization of the Mitochondrial 
DNA Polymerase of Plasmodium falciparum 
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Conserved Domain Analysis of Mitochondrial DNA Polymerases 
 The mitochondrial DNA polymerase of Plasmodium falciparum is currently 
a putative gene, with no previous genomic studies completed.  The function of this 
protein has been proposed based on conserved domain regions within the protein 
sequence to known polymerases.  Localization of this protein to the mitochondrial 
is indicated by a mitochondrial targeting sequence encoded at the beginning of the 
predicted protein.  Utilizing this targeting sequence is a strategy that has been 
used to identify multiple nuclear genes that encode proteins which localize to the 
mitochondria.  Given this information, further investigation of the conserved 
domains within the mtDNAP of P. falciparum (PfmtDNAP) can be completed 
using available databases. 
 In general, the conserved catalytic domain of the PfmtDNAP falls in the 
DNA polymerase A family as shown in Figure 3.1A, one of six families of 
polymerases classified primarily by the family of the organism and the overall 
function of the polymerase (48).  The polymerase A family includes polymerases 
with homology most similar to Escherichia coli polymerase I, and function to fill 
DNA gaps during DNA repair, recombination and replication (49).  The complete 
family with specific sub-families are listed in Figure 3.1D.  For reference, the 
mitochondrial polymerases of Saccharomyces cerevisiae and Homo sapiens were 
also analyzed (Figure 3.1B-C), with the latter offering particular interest as the 
host organism.  Both organisms demonstrated conserved catalytic domains within 
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the DNA polymerase A family, and as expected fell into the more specific gamma 
sub-family.  The gamma sub-family consists of polymerases responsible for DNA 
replication and repair within the mitochondria (49). 
 The PfmtDNAP surprisingly lacked homology with the gamma sub-family, 
and fell into the more general category of polymerase family A.  To further 
investigate the significance of this homology, the alignment of PfmtDNAP with 
DNA polymerase family A (pfam00476) was generated, shown in Figure 3.2A.  
The low e-value of 6.12e-61 indicates significant conserved domain homology 
between PfmtDNAP and family A based on the protein sequence, however some 
divergence is observed between specific amino acid residues (Figure 3.2A).  The 
mtDNAP of H. sapiens demonstrated nearly perfect alignment with the gamma 
sub-family shown in Figure 3.2B, confirming the conserved domain function in 
mitochondrial DNA replication.  The PfmtDNAP was then aligned with the 
catalytic subunit of the H. sapiens mtDNAP to confirm divergence between 
pathogen and host, with the full alignment listed in Appendix III.  This 
divergence is critical for potential drug development, should the PfmtDNAP prove 
to be an anti-malarial drug target, to eliminate unwanted drug interactions with 
the host. 
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A  H. sapiens DNA polymerase subunit gamma-1 (UniProtKB - P54098) 
 
 
B  S. cerevisiae DNA polymerase gamma (UniProtKB - P15801)  
 
 
C  P. falciparum DNA polymerase 1, putative (UniProtKB - C6KT89) 
 
 
D   
 
 
Figure 3.1:  Conserved domains of multiple mitochondrial DNA polymerases.  The 
mtDNAP of H. sapiens (A) and S. cerevisiae (B) show homology with the DNA 
polymerase A superfamily, specifically with the DNA polymerase gamma subfamily.  
The mtDNAP of P. falciparum (C) shows homology with the DNA polymerase A 
family.  D.  The sub-family hierarchy of the DNA polymerase A family, with the DNA 
polymerase gamma subfamily primarily involved in mitochondrial DNA replication.  
Conserved domains and images were generated by the NCBI Conserved Domain 
Database (49). 
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A 
 
 
B 
 
 
Figure 3.2: Protein alignments of mitochondrial DNA polymerases.  A. P. falciparum 
mtDNAP (UniProtKB - C6KT89) is more closely related to DNA polymerase Family 
A.  B. H. sapiens mtDNAP (UniProtKB - P54098) is more closely related to the DNA 
polymerase gamma subfamily.  Alignments generated by NCBI Conserved Domain 
Database (49). 
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Figure 3.3: Conditional knockdown mechanism.  The aptamers are encoded 
within the 3’-UTR of the mtDNAP gene, so while under anhydrotetracycline (aTc) 
pressure, aTc will bind to TetR preventing the protein from binding to the 
aptamer, allowing translation to occur normally. Removal of aTc will result in a 
conditional knockdown of mtDNAP by blocking translation due to sequestration 
of the transcript mRNA. 
 
 
 
Mechanism of Inducible Knockdown 
 The mechanism of the aptamer inducible knockdown system is a new and 
unique tool designed by Ganesan et al., providing controlled expression of the 
protein of interest (45).  The plasmid is designed with a Tet repressor protein 
(TetR) and aptamers, which allow anhydrotetracycline (aTc)-dependent regulation 
of transcript.  The aptamers are encoded within the 3’-untranslated regions (UTRs) 
of the target gene, so while under aTc pressure aTc will bind to TetR preventing 
the protein from binding to the aptamer, allowing translation to occur normally, 
shown in Figure 3.3.  Without aTc, TetR will bind to the aptamer region of the 
messenger RNA transcript, blocking translation due to sequestration of the 
transcript mRNA resulting in a knockdown of the gene expression (Figure 3.3).  
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Their study demonstrated that by fusing TetR to DOZI (PF3D7_0320800), a 
putative ATP-dependent RNA helicase, there was increased translation regulation 
when used with a 3’-UTR aptamer.  The TetR-DOZI system was successfully used 
to knockdown P. falciparum ATPase4, resulting in blood stage parasite death and 
establishing that the gene is essential (45).   
 Construction of the pMG75/mtDNAP plasmid resulted in loss of two 
aptamer copies, a common occurrence due to the repeating nature of the aptamer 
sequence, leaving eight copies in the final construct (data not shown).  Studies by 
Ganesan et al. have demonstrated that a minimum of six copies is required for 
successful knockdown of the protein (personal communication), allowing the final 
pMG75/mtDNAP plasmid with eight copies to be used confidently in later 
experiments.   
 
Generation of Transgenic Parasites 
Transgenic parasites with integrated pMG75/mtDNAP plasmid DNA have 
aptamers encoded within the 3’-UTR of the mtDNAP gene.  Integration of the 
pMG75/mtDNAP occurs by single crossover recombination with the parasite 
gDNA, utilizing the mtDNAP homology region within the plasmid.  This 
mechanism relies on random double stranded breaks in the parasite gDNA for 
recombination to successfully occur, illustrated specifically in Figure 3.4A.  As 
previously stated, the pMG75/mtDNAP plasmid is designed for single crossover 
40 
 
  
 
recombination to occur immediately before the stop codon of the mtDNAP gene 
within the 3’-UTR, allowing full replication and transcription of the integrated 
plasmid DNA to occur along with the parasite gDNA.  
D10 parasites transfected with the pMG75/mtDNAP plasmid recovered after 
three weeks.  Parasites were harvested for DNA, and PCR analysis was conducted 
to determine if integration of the plasmid was successful, as well as presence of 
resistant wild type parasites and length of the aptamer.  The expected band sizes, 
illustrated in Figure 3.4B, are as follows: 1.3kb for integration, 1.8kb for resistant 
wild type parasites, and 2.4kb for full length aptamer with eight copies.  
Integration was not achieved immediately, therefore parasites were drug cycled for 
one full month to eliminate presence of episomal plasmid and select for parasites 
only with integrated plasmid DNA.  After one drug cycle integration was 
successful, however only two copies of the aptamer remained, with PCR results 
shown in Figure 3.4C.  Loss and deletion of aptamer copies has been previously 
observed by our laboratory, and tends be lost as stated due to the repetitive nature 
of the aptamer sequence.   
In an attempt to generate parasites with full length aptamers, frozen stocks 
of parasites prior to the drug cycle were used for two more independent drug 
cycles.  An additional transfection in D10 was conducted and drug cycled, as well 
as a transfection in NF54 with no drug cycling.  DNA was collected from all 
parasite lines in various conditions, including independent transfections in either 
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D10 or NF54 wild type parasites, and if the parasites were drug cycled.  PCR results 
using these parasite lines listed in Table 3.1 are shown in Figure 3.5.  The 
transfection in NF54 demonstrated integration with full aptamer, but was not used 
due to low integration signal compared to other parasite lines.  Aptamer loss was 
observed again in the second D10 transfection with drug cycling, with no 
integration observed in the line prior to drug cycling.  The repeated drug cycle of 
the first D10 transfection from frozen stocks provided a line with integration and 
full length aptamers.  This line was used for cloning to eliminate resistant parasites 
with episomal plasmid from the culture.  One transgenic clone, referred to as E6, 
was obtained with integration of the transgene bearing full length aptamers, and 
no wild type parasites, as determined by PCR reactions shown in Figure 3.6. 
Transfections in D10 parasites were also conducted with the pUF-
1/mtDNAP plasmid and three guides in the Cas2A plasmids.  Integration of this 
plasmid occurs by double crossover recombination of the 3’- and 5’- homology 
regions after the cleavage of the gDNA by Cas9 determined by the specific guide 
RNAs.  Parasites were recovered from transfection after seven weeks, but screening 
by PCR determined that only wild type parasites were present (data not shown). 
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Figure 3.4: Generation of integrated transgenic parasites.  A. Integration of the 
plasmid into the parasite genome by single crossover recombination with the 1kb 
homology region to the gDNA of the parasite, placing the plasmid within the 3’UTR 
after the mtDNAP gene.  B. Primer binding regions and expected PCR band size for 
integration, aptamer length, and wild type, with specific primers listed in Table 2.2.  
C. D10 transgenic parasites after one drug cycle with integrated plasmid and two 
out of eight copies of the aptamer, confirmed by sequencing (data not shown).    
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Figure 3.5:  Generation of integrated transgenic parasites with full length aptamer.  
Multiple transfections and drug cycling completed to generate mixed culture 
parasites with integrated pMG75 plasmid DNA and eight copies of the aptamer as 
confirmed by PCR shown above, with primers listed above the lanes (Table 2.2) and 
lane contents indicated in Table 3.1.  Expected band sizes are indicated in Figure 
3.4. 
 
Lanes Transfection WT Parasite 
Line 
Integration? Drug 
Cycle? 
Aptamer 
Length 
1, 4, 7 2 D10 N N - 
2, 5, 8 1 D10 Y Y 2 
3, 6, 9 1 D10 N N - 
10, 13, 16 3 NF54 Y N 8 
11, 14, 17* 1 D10 Y Y 8 
12, 15, 18 2 D10 Y Y 2-4 
Table 3.1: Generation of integrated transgenic parasites with full length aptamer. 
Characteristics of mixed culture transgenic parasite lines of multiple transfections, 
and some after one drug cycle, with PCR results demonstrated in Figure 3.5.  Each 
row is indicative of an independent parasite culture.  *Transgenic parasite line used 
for cloning.  
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Figure 3.6:  Screening of transgenic parasite clones.  One successful clone was 
achieved, referred to as E6, indicated by presence of integrated plasmid and full 
length aptamer, and no presence of wild type parasites. 
 
 
 
Localization of mtDNAP Could Not Be Determined 
 Immunofluorescent analysis (IFA) was used in an attempt to visualize the 
localization of the transgenic mtDNAP in the E6 clone.  In multiple attempts of 
IFA staining of E6 parasites, the mtDNAP could not be visualized, whereas DAPI 
and mitochondrial staining was observed normally (data not shown).  Successful 
protein tagging was demonstrated by Western blot analysis (Figure 3.7), however 
long exposure with the most sensitive substrate was required to visualize the 
protein, indicating very low expression of the mtDNAP.  Due to this low level of 
expression and the availability of only a single Myc tag for IFA staining, it is likely 
that the protein cannot be visualized by IFA in the E6 clone.  Protein tagging with 
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a triple HA tag might be a better option for IFA analysis due to increased binding 
sites and higher sensitivity, as discussed further in the next chapter. 
 
mtDNAP Can Be Successfully Knocked Down 
 A knockdown assay was conducted with the E6 cloned parasites, with 
samples collected over the course of 20 days, or 10 cycles.  Western blot analysis 
was conducted on samples from cycles 1, 4, 7 and 10, with and without aTc.  The 
expected size of the mtDNAP is approximately 170 kDa.  Protein expression at the 
proper size was observed in all samples in which aTc was maintained as shown in 
Figure 3.7.  Knockdown was observed after the first cycle without aTc, and was 
maintained in the remaining cycles (Figure 3.7).  Aldolase controls indicate 
presence of parasites in all samples, confirming appropriate loading of all samples.  
As previously mentioned, the protein expression of mtDNAP is relatively low, 
requiring a strong substrate and film exposure of at least five minutes in order to 
visualize Western blot bands.  Due to this low expression, densitometry between 
the normal and knockdown Western blot bands cannot be conducted to 
determine the exact amount of knockdown that is occurring.  Overall, knockdown 
of the mtDNAP was successful with no protein detectable by Western blots.  
Parasites were maintained over the course of 20 days with no parasite death 
observed, extending to over two months with no change in growth rate (data not 
shown).  This observation suggests that the mtDNAP expression can be knocked 
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down below the detection level without affecting parasite survival in the asexual 
blood stage. 
 
Knockdown of mtDNAP Does Not Alter Parasite Growth  
 Samples from the same knockdown assay described above were collected 
daily to determine the parasitemia over time.  Parasitemia was determined by 
SYBR green staining of the parasite nuclear material and measurement with flow 
cytometry.  The growth of the E6 parasites, with and without aTc, was plotted on a 
Log10 scale over time, shown in Figure 3.8.  No difference in growth was observed 
between conditions, with a P-value of 0.9286 indicating no statistical significance 
(Figure 3.8).  Knockdown was confirmed by Western blot (Figure 3.7), 
demonstrating that reducing the mtDNAP expression below the detection level 
does not affect the growth rate of the parasites. 
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Figure 3.7:  Western blot demonstrating knockdown of mtDNAP.  Protein 
expression of mtDNAP can be observed in samples with aTc, with the expected size 
of 170 kDa, while samples without aTc have no observable protein expression.  
Aldolase is shown as a parasite loading control, observed in all samples. 
 
 
 
 
Figure 3.8:  Growth rate of E6 clone is not affected by knockdown.  No difference 
in growth was observed between parasites with and without aTc.  Fixed parasite 
samples were stained with SYBR green to determine parasitemia by flow cytometry.  
The Log10 of the parasitemia was determined for each sample. 
 
0
1
2
3
4
5
6
7
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
P
a
ra
s
it
e
m
ia
 (
L
o
g
1
0
)
Day
Growth Rate of E6 Clone
+aTc -aTc
48 
 
  
 
Transgenic Knockdown Parasites Demonstrate Decreased mtDNA 
 To further investigate the effect of mtDNAP knockdown, the amount of 
mtDNA present without the mtDNAP was determined using DNA samples 
collected during the knockdown assay.  Knockdown of the mtDNAP is expected to 
result in less mtDNA, as there is no other annotated polymerase that could carry 
out mtDNA replication.  The cytochrome b gene was used to quantify the mtDNA.  
The presence of cytochrome b was confirmed by PCR, with the gene being present 
in all samples from the knockdown assay (Figure 3.9A).  Integration and length of 
aptamer were also confirmed by PCR, with integration and full aptamer 
maintained throughout the assay, eliminating the possibility of aptamer deletions 
affecting knockdown efficiency (Figure 3.9B).  Quantitative PCR analysis was used 
to determine the copy number of the cytochrome b gene in parasites grown with 
or without aTc, using GAPDH as a nuclear gene control.  The fold change in 
cytochrome b gene copy number was calculated for each cycle and controlled to 
parasites with aTc maintained.   
The knockdown E6 parasites demonstrated decreased levels of cytochrome 
b copy number relative to normal E6 parasites with aTc, and therefore a decreased 
amount of mtDNA as expected (Figure 3.10).  On average, there was 
approximately a 70% decrease in mtDNA observed in the E6 knockdown parasites.  
After the first cycle, knockdown parasites had 40% decrease in the mtDNA 
compared to parasites with aTc, with the fold change of mtDNA decreasing to 
49 
 
  
 
approximately 70% by the fourth cycle which was maintained in the remaining 
cycles.  This confirms that knockdown of the mtDNAP does result in decreased 
mtDNA replication, demonstrated by the decreased amount of mtDNA.  The 
remaining 30% of the mtDNA in knockdown parasites must be sufficient for 
parasite survival, and possibly indicates that the knockdown of mtDNAP is not 
complete, with some protein still being expressed.    
 
 
 
 
 
A            B 
 
 
Figure 3.9:  PCR analysis of knockdown assay.  DNA samples were collected every 
cycle at trophozoite stage.  PCR analysis of cytochrome b, integration and aptamer 
length were conducted.  A. Cytochrome b is present in all samples.  B. Integration 
and aptamer length were maintained throughout knockdown assay, as shown by 
cycle 1 and cycle 10 samples with and without aTc. 
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Figure 3.10:  Quantitative PCR measurement of mtDNA copy number.  DNA 
samples were collected from parasites grown with and without aTc from days 2, 8, 
14, & 20 of the knockdown assay and used for qPCR analysis.  Fold changes of the 
cytochrome b copy number of parasites without aTc compared to with aTc were 
plotted.  Decreased copy number is observed in parasites without aTc. 
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Transgenic Knockdown Parasites Are Not Sensitive to Drug Inhibitors 
 The growth of transgenic E6 parasites and knockdown parasites was 
analyzed in the presence of atovaquone, proguanil, and ethidium bromide.  A 
decreased amount of mtDNA should in theory decrease the protein expression of 
electron transport chain components encoded from the mtDNA, and thus can be 
expected to render the parasite more sensitive to atovaquone and proguanil.  
Ethidium bromide causes DNA damage, and was used to assess DNA repair 
activity of mtDNAP under normal and knockout conditions.  The percentage of 
parasite growth was plotted against the concentration of each drug treatment 
(Figure 3.11).  For all treatments, no difference was observed between normal and 
knockdown parasites, with death eventually resulting from all treatments at the 
indicated concentrations (Figure 3.11).  This result further demonstrates that the 
remaining mtDNA in knockdown parasites is sufficient for survival, and does not 
alter the susceptibility of the parasites to drug inhibitors.  
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Figure 3.11:  Growth inhibitory assays with various drug treatments.  E6 parasites 
with and without aTc were treated independently with atovaquone, proguanil, and 
ethidium bromide.  Percent growth is plotted against the amount of drug treatment, 
with IC50 values shown below the graph.  No significant difference in IC50 was 
observed from any of the treatments between parasites with and without aTc.  
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Chapter 4: Discussion & Future Directions 
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Discussion 
 Limited research has been conducted on the mitochondrial DNA 
polymerase of Plasmodium falciparum, providing little insight into the nature of 
the protein, but allowing many possibilities for future studies.  The aim of this 
thesis was to shed light on the mitochondrial DNA polymerase and characterize its 
functions through a genetic approach.  The mtDNAP was successfully knocked 
down in P. falciparum blood stage parasites, demonstrating no growth phenotype 
after many cycles, as well as no change observed in response of the parasites to 
drugs targeting mitochondrial functions.  However, the quantity of the mtDNA 
was decreased in knockdown parasites.  Although the results were not as expected, 
it is consistent with the suggestion that this protein is in fact responsible for 
replicating the mitochondrial DNA, with the matter of its essentiality remaining 
left to be explored.   
 Generating a cloned line of transgenic parasites with the pMG75/mtDNAP 
plasmid proved difficult initially in the study, with aptamer deletions being the 
main issue.  Aptamer deletions have been observed by our laboratory previously, 
and is likely due to the repetitive nature of the aptamer sequence.  Given this 
knowledge, the aptamer length must be frequently checked to confirm its presence 
even after generation of cloned transgenic parasites.  Eventually, a mixed culture 
with integration and a stable full length aptamer was able to be cloned, providing 
us with the E6 clone for experiments.  During the knockdown assay using the E6 
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clone, lack of a growth phenotype was observed early on, as parasite death would 
be expected quickly should the mtDNAP be essential.  Given this observation, the 
assay was carried over a full 10 cycles for adequate data collection.  
 Western blot analysis confirmed successful knockdown of the mtDNAP, 
with no protein expression detectable in any of the knockdown samples, compared 
to transgenic parasites with aTc maintained in culture.  Given no signal in the 
knockdown parasites, it was initially assumed the knockdown was completely 
successful, and that the mtDNAP was non-essential for parasite survival.  Upon 
mtDNA quantitation of samples from the assay, we discovered that the mtDNA 
was greatly reduced in knockdown parasites, indicating that the mtDNAP is in fact 
a polymerase that has a role in replicating the mtDNA.  This led to many questions 
as to role of this protein and the actual level of knockdown that was achieved.  
 Typically, densitometry of Western blots is used to determine the exact 
level of knockdown achieved.  In this case, that could not be conducted given that 
there was no observable protein expression at all by Western blot analysis.  In 
order to observe protein expression in the transgenic parasites without 
knockdown, our most powerful substrate (“West Femto” reagent) plus long 
exposure times were required to see the faintest signal.  This issue was also evident 
when conducting IFA analysis, as no observable signal was detected after multiple 
attempts of fluorescent staining of transgenic parasites.  This leads us to believe 
that the mtDNAP is normally expressed at low levels, so in the case of a partial 
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knockdown, it is likely that an even lower level of expression would be 
undetectable.  Given the presence of mtDNA in knockdown parasites, we suggest 
the knockdown to be partial, as a full knockdown would have resulted in no 
replication of the mtDNA, and thus no mtDNA remaining over time.  Further 
study is required to determine the exact level of knockdown achieved, and 
alternative methods to generate a complete knockdown of the mtDNAP. 
 The mtDNA provides an essential role for P. falciparum blood stage 
parasites, encoding genes for the mtETC proteins cytochrome c oxidase subunits 1 
and 3, and cytochrome b (5, 30).  Without the mtDNA, parasites could not survive 
due to the reliance on the mtETC for pyrimidine biosynthesis and maintenance of 
the mitochondrial proton gradient (29).  In the qPCR analysis of the knockdown 
mtDNA, there was on average a 70% decrease of the total mtDNA in knockdown 
parasites.  With no change in growth rate observed, it is clear that approximately 
30% of the mtDNA is sufficient for parasite health and survival.  Parasites contain 
approximately 30 copies of the mtDNA, so it is possible that although the mtDNA 
is decreased, there are enough copies remaining for adequate protein production 
for the mtETC (35).     
The knockdown parasites were unaffected by the various drug inhibitors.  
Atovaquone targets cytochrome b of the mtETC, a protein encoded by the mtDNA 
(20).  Given the decreased amount of mtDNA in the knockdown parasites, overall 
protein expression could be decreased as well, resulting in the parasites with 
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greater susceptibility to the drug.  We observed no change in growth in the 
presence of atovaquone, and also no difference with proguanil, a drug which 
disrupts the membrane potential generated by the mtETC (30).  Although the 
mtDNA is decreased, there are multiple copies of the mtDNA normally present in 
the mitochondria, so the protein expression from the mtDNA in knockdown 
parasites is likely unaffected.  Growth inhibitory assays were also conducted with 
ethidium bromide, a known DNA mutagen, to determine its effect on parasite 
growth and shed light on the possibility of the mtDNAP having DNA repair 
activity.  Given there was no difference observed in knockdown parasites, it is 
likely that this assay is unlikely to assess mtDNA repair in parasites. 
This thesis effectively characterized the putative mitochondrial DNA 
polymerase of Plasmodium falciparum.  Ground work has been established to allow 
more in depth research is required to fully understand the role of this protein in 
parasite survival, a starting point has been established.  We have successfully 
confirmed that the mitochondrial DNA polymerase does have a role in 
mitochondrial DNA replication, and hope to extend on these findings in future 
research.   
 
 
 
 
58 
 
  
 
Future Directions 
 The nature of this project was exploratory, and has provided many 
opportunities for future research.  There were many issues with the low expression 
of mtDNAP.  To alleviate this problem, a construct using a triple HA tag, rather 
than a single Myc tag, would be very beneficial for both western blot and IFA 
analysis.  Utilizing a triple HA tag provides greater binding sites for antibodies, 
allowing better observation of the tagged protein.  The pMG75 plasmid is currently 
being modified with the triple HA tag, for future use within our lab.  This will 
provide greater insight into the localization of the mtDNAP, and more accurate 
western blot analysis of protein expression. 
 We believe that our knockdown was only partial, and a clean knockdown 
for future research is necessary.  To achieve this, a double crossover recombination 
mechanism utilizing CRISPR-Cas9 to knock in the pMG75 plasmid will be utilized.  
This design allows the use of multiple guide RNAs, generating a line of transgenic 
parasites immediately without the requirement of cloning.  This mechanism is less 
variable than the current single crossover mechanism, and should provide a line of 
transgenic parasites that can more effectively be knocked down with minimal 
variation. 
 Greater analysis of the mtDNA in knockdown parasites is crucial to fully 
understand the effect of decreased mtDNAP.  The qPCR analysis will be repeated 
with increased biological replicates to determine the statistical significance of our 
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findings, as well as confirm results achieved in this study.  Of interest is 
conducting sequencing of the mtDNA, to determine the exact copy number 
present in knockdown parasites and the possibility of mutations in the mtDNA as 
a result of the knockdown. 
 Lastly, we would like to knockdown the mtDNAP in the presence of 
yDHODH.  As previously discussed, presence of yDHODH allows blood stage 
parasites to function independently of the mtETC (30).  Due to the reliance of the 
mtDNA to produce essential proteins for the mtETC, we would expect the 
yDHODH to compensate for knockdown of the mtDNAP, allowing the production 
of a transgenic parasite line completely lacking the mtDNA.  This has been a long 
term goal of the lab, and can be achieved utilizing the pMG75 mechanism in 
tandem with yDHODH background. 
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>PF3D7_0625300  | Plasmodium falciparum 3D7 | DNA polymerase 1, 
putative | genomic | Pf3D7_06_v3 reverse | (geneStart+0 to 
geneEnd+1000) | length=5335 
ATGAAATTGTTTGATTCATTTTTTAAACATGCTTTGATAAGAATAAATAAAAGGAATATAATATATTTGAA
TGCCACTAGGTACTATTGTAATAACATAAATTATAATGCTTTGATAAATTTGTTAAATAAGAAAAATGATA
TAAATAAAGAAATAAATGCCTTATATTCTTTATTAGAAAGACTGTCAAATTATAAGTACAAACAATATAAA
GATAAGTTGACTCTGAAAAATAATATAAACGATGAAATTAAAATAACAAATGCTGATAAAATTAATAATAT
AAATATTGAAAGGGATATGAATATTTCTCATTTGGATCATCATCATAATAATCATCATCATAATAATAATC
ATCATAATATTAATCATAATAATCATCATCATAATAATCATCATAATATTAATCATCATAATAATCATCAT
AATAATCATCATAATAATAATCATTTTAATGATTATAAAAAACTAATTGATAATTGGAAAAATGATAAAAT
AAAAATATTTATAAGCTGGTGTCCCGAAATTGTTGAAGATAAATATAAGTCCAAATGTTTCTCTATACCAA
CTTATATCACATTTCATATTGTTATAACTAATAATGATATTAAGTTGAATAACCTTTTGCATAATTCTCAT
GAATATGATGATTGGAACTTTAATAAAATAATACAAACAATAAATAATCAAAACAATTTAAAAGATAAAGA
AAAGGAAAAAGAAAATGGACAACAACATTCACAAGAATATATTGGAAATTGTAAAAAGGGAGAATCTGAAA
TACCATCATATGATTTCAAAGAATCTTTATTAGAACACATAAATGAATCTTCACAATTAAATCATTCCATA
TTATCGCACAAAACAAAAGAACAAACCCATCATACTAATAATAATATAAATGGTAATTATAATAATGATGA
ACATATTGAAGAAGAGGGAAAGGCAAAAACAAAACAAAACAAAACAAAAAATAGCATAATAGAGGAAAAAA
AAAAAAAGACAAAAAAAAAAAAAGATGAAGAATCTCATAATGATATAATAAATTATACTATAAAGAAAAAA
ACAAATACAAATAATTCATTATATAATATAGAATCAATCTTAAATATACCAAAAACTTATGAACCTAATAT
ACATTATGATAAATGTATACATAAAGAACAAAATCATATTTTTTTCTTTTCCTTTAATATATCCGAATTAA
TAATTAATGATCAAGTAAAAACAAAATTGAATGAATGTATTCAACAAAATTTTATAAAACAAAATATATCA
AATATACATATGGATGATCTTTTTTTATATGTTGTATATGATTATAAAAATTTAATACATATATTTAATAA
TATTAATTTAAAATTAATAAATATTAATAATATATTTGATATATATATTATTAGTTCACTAATACAATTAG
TTCAAAGAGGGGAAAAATTACAAAATGTGTATAATGAATATTTAAATGTTAAACATAAAATTCTTATACCT
AATAAAATTAATGATATACAAAATTTAAGTCTTCATAATTTTTCGTATTTTTCAAAGTTTGCTCCTGAATT
TAGCGATGTCATATCAGCAAAGTTTGGGTTATATGGTTGGGGAAAATATCAAAAGAAAAAAGATAAGAAAA
ATAAAAAACAAACTGAAAATCATGAAAATAATGAAAATTATGAAAATAATGAATACGGTAAAAATAATGAA
TATGGTAAAAATAATGAATATGGTAAAAATAATGAATATGGTAAAAATAATGAATATGGTAAAAATAATGA
ATATGGTAAAAATAATGAATATGGTAAAAATAATGAATATGGTAAAAATAATGTACACAATGACGATACAT
ATATGGACATATCAAATGAGAGAAAGAATAAGAAGAGTAAAGAAGTCAAAAACAAAAAAAAGATGGAGAAA
AAAAACAAAGTAGAAAAAGAAAAACAAAATTATTTAAGTTTTACTCCTCATAATATAAATAATCTTCAAGA
TATTAAAAAACTTGTATTTGGGAATAAAAGAAATATATCAGATATTACAGAAGAAGATAATATATGTTATA
GTATATCACGAAATTGTTGTTTAATTTTACTATTTGAATATTTCATAAATAAATTAGAACATAATATCAAC
ATACTAAATTTATACATCAAAGTTGAACAACCATTAATATTATGTATAAGTCATATAGAGGAAAAAGGAAT
CTTCTTGAATCAAAATAAAATTGAAGAAATACAAAAAAAATCAGATGACCCTTTAATATATAAAAATGAAA
TTGAAGAATTATGTAAATGTAATATTAATTTGAATTCATCCAAGCAAGTCTCTTCATTGATATATAAACAA
TTATTAGACATATCCATTAGCACAGATCACACGGAAGAAAATATGGAAGATGCAGATGAACATACAGATCA
CCAGGAAGAAGAACATGTAAATGATGATAATAATGAATGTGTAGATCAATTAAAAGCATATACTCAAACAA
AGGAAAAAGAAAGAAAAGACATATATAATAATAATAATAATGAAAATAATAAAAATAATAATGAAAATTAT
AATTCAAGTAAAAATCATCCTTTAATAACAAATACTAATAACGATGATACATCTACACTTAATGCACAAGA
TACATCTGACCAACATGATAATTATATAAATGAACATAATAATTATAATAAATTTATAAAAAATAACCCTT
TTTACTATAATAATAATAATAATAATAATAATAATAATAATAATAATAATGATAATAATAATAATATTTCT
AATCGTAATCTTATGAACAATCTTGTAAACATTAATTACACTTCATTATATAATAAAAAGAAAAATAGTCA
TCCATATGATGAAAATAATAAGTTGTTTTTCCTCAACAGCAGCCATAATAATTATAATAATAATAATAATA
ATATTAACGAAATGAGCAGAAACAAAAATCTACAAACCAATAATAAGTCATTAAAAATTCTTGTCGATGAA
ATTGAAAAAAGTAATTATATAAAAGAAAAGGAAAAAGAAAAATTAAAAAAAATTATTAGAAATATTAAATT
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ATATAGAGAATCTAAAAAATTAGTACAAAATTATATAGAAAATCTCCCTAAATATATACAAAAAAATACAA
ATAAAATACATTGTAATTTTAATCAAATTGGAGCATCAACAGGAAGATTATCTTGTGATCAACCAAATTTG
CAAAATATACATTCACGATTTCGTTGTGCTATATCGTTAAAAGGTAAGGAAGAAAATGACACACATGATAA
TAATAATAATAATAATAATATACCACAGATTCATATATCAACTAATAATGTATCAACCAATAATGTACCCA
TGAATATCATGTCATCTACATATCCTTTATATACCATGAATAAAAAAAATTTAATCACCTTCGATTATAAA
CAAATGGAATTATTTGTCATGGCATATCTCAGTTTTGATGAACAATTATTGAAATTATTAAATTATAGTGA
TGTATTTATCGAAACAGCCAAAGTATTATTTAATACAAATGATGTTACCAATGAATTAAGAAGAATGACCA
AAACTGTTATATATGGTATATTATATGGACAAACTGAAAATGGACTAGCCAAAAGTTTATTAATTAGCGAT
ACTTTGGCTAGTAACCTAATAGAAAACTTTTTTCAATTTTTTCCAAACGTATATCGATTTATGCAAATGCA
GAAATTTTTAGTCAAACATATGAATTGTGTTTATACACTTATAGGAAGGAAAAGAATAATATTACCAAACA
TTAAAAATAAATATAGGATAAGTATGAATACACCTATACAAGGATGTGCAGCAGATATTATGAAATTTTCT
CTCTTGTCATGTTTTAGTGTTCTTAATAATAATATATATAATAACAATAAATTATTAAAAATGAATAATAT
AAATCCTTTAATCATACATAAAAATCAAGCCTTTTTAAATCCAACTAATTTAATTTTGCAAGTACATGATG
AATTATTATTAGAAAGTGAACATGATGCTACCAAATATATAATACAACTACTAAATCCTATATTAGAAAAT
GCTTTTTATAATTTAATTTATTATACGAACTCTATAGATAGACTTAAACTATTATATGATTATATGCATGA
TAATATTTCTATCAAAACATATATAGATATTTTACAAGATATAAATAACAAACAATATAATGATGTAAAAT
TATACAATGGTGTATATAATACAAATGTATCAGAAGAATCACACATATATAATATATCAAATAATGTGGAT 
CATATATTTCAAAAATTTAATTTTAAGTTGCCTATTAAAGTTGAATCAGGCGGAGTCTACAAGGAGTCTTC
ATAA 
Appendix I.  Binding regions of primers for the mtDNAP 1027 bp homology region 
cloned into the pMG75 vector.  Primer binding regions are highlighted in yellow and 
the homology region highlighted in grey. 
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>PF3D7_0625300  | Plasmodium falciparum 3D7 | DNA polymerase 1, 
putative | genomic | Pf3D7_06_v3 reverse | (geneStart+0 to 
geneEnd+1000) | length=5335 
ATGAAATTGTTTGATTCATTTTTTAAACATGCTTTGATAAGAATAAATAAAAGGAATATAATATATTTGAA
TGCCACTAGGTACTATTGTAATAACATAAATTATAATGCTTTGATAAATTTGTTAAATAAGAAAAATGATA
TAAATAAAGAAATAAATGCCTTATATTCTTTATTAGAAAGACTGTCAAATTATAAGTACAAACAATATAAA
GATAAGTTGACTCTGAAAAATAATATAAACGATGAAATTAAAATAACAAATGCTGATAAAATTAATAATAT
AAATATTGAAAGGGATATGAATATTTCTCATTTGGATCATCATCATAATAATCATCATCATAATAATAATC
ATCATAATATTAATCATAATAATCATCATCATAATAATCATCATAATATTAATCATCATAATAATCATCAT
AATAATCATCATAATAATAATCATTTTAATGATTATAAAAAACTAATTGATAATTGGAAAAATGATAAAAT
AAAAATATTTATAAGCTGGTGTCCCGAAATTGTTGAAGATAAATATAAGTCCAAATGTTTCTCTATACCAA
CTTATATCACATTTCATATTGTTATAACTAATAATGATATTAAGTTGAATAACCTTTTGCATAATTCTCAT
GAATATGATGATTGGAACTTTAATAAAATAATACAAACAATAAATAATCAAAACAATTTAAAAGATAAAGA
AAAGGAAAAAGAAAATGGACAACAACATTCACAAGAATATATTGGAAATTGTAAAAAGGGAGAATCTGAAA
TACCATCATATGATTTCAAAGAATCTTTATTAGAACACATAAATGAATCTTCACAATTAAATCATTCCATA
TTATCGCACAAAACAAAAGAACAAACCCATCATACTAATAATAATATAAATGGTAATTATAATAATGATGA
ACATATTGAAGAAGAGGGAAAGGCAAAAACAAAACAAAACAAAACAAAAAATAGCATAATAGAGGAAAAAA
AAAAAAAGACAAAAAAAAAAAAAGATGAAGAATCTCATAATGATATAATAAATTATACTATAAAGAAAAAA
ACAAATACAAATAATTCATTATATAATATAGAATCAATCTTAAATATACCAAAAACTTATGAACCTAATAT
ACATTATGATAAATGTATACATAAAGAACAAAATCATATTTTTTTCTTTTCCTTTAATATATCCGAATTAA
TAATTAATGATCAAGTAAAAACAAAATTGAATGAATGTATTCAACAAAATTTTATAAAACAAAATATATCA
AATATACATATGGATGATCTTTTTTTATATGTTGTATATGATTATAAAAATTTAATACATATATTTAATAA
TATTAATTTAAAATTAATAAATATTAATAATATATTTGATATATATATTATTAGTTCACTAATACAATTAG
TTCAAAGAGGGGAAAAATTACAAAATGTGTATAATGAATATTTAAATGTTAAACATAAAATTCTTATACCT
AATAAAATTAATGATATACAAAATTTAAGTCTTCATAATTTTTCGTATTTTTCAAAGTTTGCTCCTGAATT
TAGCGATGTCATATCAGCAAAGTTTGGGTTATATGGTTGGGGAAAATATCAAAAGAAAAAAGATAAGAAAA
ATAAAAAACAAACTGAAAATCATGAAAATAATGAAAATTATGAAAATAATGAATACGGTAAAAATAATGAA
TATGGTAAAAATAATGAATATGGTAAAAATAATGAATATGGTAAAAATAATGAATATGGTAAAAATAATGA
ATATGGTAAAAATAATGAATATGGTAAAAATAATGAATATGGTAAAAATAATGTACACAATGACGATACAT
ATATGGACATATCAAATGAGAGAAAGAATAAGAAGAGTAAAGAAGTCAAAAACAAAAAAAAGATGGAGAAA
AAAAACAAAGTAGAAAAAGAAAAACAAAATTATTTAAGTTTTACTCCTCATAATATAAATAATCTTCAAGA
TATTAAAAAACTTGTATTTGGGAATAAAAGAAATATATCAGATATTACAGAAGAAGATAATATATGTTATA
GTATATCACGAAATTGTTGTTTAATTTTACTATTTGAATATTTCATAAATAAATTAGAACATAATATCAAC
ATACTAAATTTATACATCAAAGTTGAACAACCATTAATATTATGTATAAGTCATATAGAGGAAAAAGGAAT
CTTCTTGAATCAAAATAAAATTGAAGAAATACAAAAAAAATCAGATGACCCTTTAATATATAAAAATGAAA
TTGAAGAATTATGTAAATGTAATATTAATTTGAATTCATCCAAGCAAGTCTCTTCATTGATATATAAACAA
TTATTAGACATATCCATTAGCACAGATCACACGGAAGAAAATATGGAAGATGCAGATGAACATACAGATCA
CCAGGAAGAAGAACATGTAAATGATGATAATAATGAATGTGTAGATCAATTAAAAGCATATACTCAAACAA
AGGAAAAAGAAAGAAAAGACATATATAATAATAATAATAATGAAAATAATAAAAATAATAATGAAAATTAT
AATTCAAGTAAAAATCATCCTTTAATAACAAATACTAATAACGATGATACATCTACACTTAATGCACAAGA
TACATCTGACCAACATGATAATTATATAAATGAACATAATAATTATAATAAATTTATAAAAAATAACCCTT
TTTACTATAATAATAATAATAATAATAATAATAATAATAATAATAATAATGATAATAATAATAATATTTCT
AATCGTAATCTTATGAACAATCTTGTAAACATTAATTACACTTCATTATATAATAAAAAGAAAAATAGTCA
TCCATATGATGAAAATAATAAGTTGTTTTTCCTCAACAGCAGCCATAATAATTATAATAATAATAATAATA
ATATTAACGAAATGAGCAGAAACAAAAATCTACAAACCAATAATAAGTCATTAAAAATTCTTGTCGATGAA
ATTGAAAAAAGTAATTATATAAAAGAAAAGGAAAAAGAAAAATTAAAAAAAATTATTAGAAATATTAAATT
ATATAGAGAATCTAAAAAATTAGTACAAAATTATATAGAAAATCTCCCTAAATATATACAAAAAAATACAA
ATAAAATACATTGTAATTTTAATCAAATTGGAGCATCAACAGGAAGATTATCTTGTGATCAACCAAATTTG
CAAAATATACATTCACGATTTCGTTGTGCTATATCGTTAAAAGGTAAGGAAGAAAATGACACACATGATAA
TAATAATAATAATAATAATATACCACAGATTCATATATCAACTAATAATGTATCAACCAATAATGTACCCA
TGAATATCATGTCATCTACATATCCTTTATATACCATGAATAAAAAAAATTTAATCACCTTCGATTATAAA
CAAATGGAATTATTTGTCATGGCATATCTCAGTTTTGATGAACAATTATTGAAATTATTAAATTATAGTGA
TGTATTTATCGAAACAGCCAAAGTATTATTTAATACAAATGATGTTACCAATGAATTAAGAAGAATGACCA
AAACTGTTATATATGGTATATTATATGGACAAACTGAAAATGGACTAGCCAAAAGTTTATTAATTAGCGAT
63 
 
  
 
ACTTTGGCTAGTAACCTAATAGAAAACTTTTTTCAATTTTTTCCAAACGTATATCGATTTATGCAAATGCA
GAAATTTTTAGTCAAACATATGAATTGTGTTTATACACTTATAGGAAGGAAAAGAATAATATTACCAAACA
TTAAAAATAAATATAGGATAAGTATGAATACACCTATACAAGGATGTGCAGCAGATATTATGAAATTTTCT
CTCTTGTCATGTTTTAGTGTTCTTAATAATAATATATATAATAACAATAAATTATTAAAAATGAATAATAT
AAATCCTTTAATCATACATAAAAATCAAGCCTTTTTAAATCCAACTAATTTAATTTTGCAAGTACATGATG
AATTATTATTAGAAAGTGAACATGATGCTACCAAATATATAATACAACTACTAAATCCTATATTAGAAAAT
GCTTTTTATAATTTAATTTATTATACGAACTCTATAGATAGACTTAAACTATTATATGATTATATGCATGA
TAATATTTCTATCAAAACATATATAGATATTTTACAAGATATAAATAACAAACAATATAATGATGTAAAAT
TATACAATGGTGTATATAATACAAATGTATCAGAAGAATCACACATATATAATATATCAAATAATGTGGAT
CATATATTTCAAAAATTTAATTTTAAGTTGCCTATTAAAGTTGAATCAGGCGGAGTCTACAAGGAGTCTTC
ATAAAAAAAATACACACCCATATGTATATATATATAGATATGTATATATATATTTATATTTATTTATTTAT
TTTGATATATATTCTTATTTTTTTAAGTAATTTATATTATTTATTGAATTAAAATTTTTCACTATTTTGAA
TTATATATATATATATATATAAATTTTTTTTTTAAGTATTGTTTTCTTATGACTAAAAAAAAAAGAAATCA
TTAAAATGTATGTATTTGTGTTTCGCATAAAGAGGATGCAAATTAAAGTATACACGACATAAAAAAATTAG
CAAAACATATATATATATATATATATATATTATTGAATGTTTTAAAGGACACATGTCCCAATACACAAAAA
AAAATTTTAAAAATGTTTTTTTTATTTTTTATTTTTTATTTTTTTTTTTTTTATTTTTTTTTTTTATTTTT
TTATTTTATTTTATTTTTTTTTATGACATAAAAATAATCCATTATTCATATATACTTTTTACTTTTAAGTG
TCCGAGAATATATCCTTATCTATCGAATTTTCAAATAATTCCTTCCCCTTCCCCTTTGCCCTTTCCTTTTT
CTTTTTTCGTATTATCTTGTTTTTTTGTTCATCATTTGAGGAAAGTGCTTCATTCATATGTACCTTTTTCT
CCAGATCATCATTAATACTTTTCAATATTTTATTTTCTTCAATTAATTTATTAAGGTTAATATCTAATTGG
TTGAAATTTGTTTGGAAATATTTCAATTTATCGATCAAAAGTGTATTTTCCTTTTTTAGTTGTTTCATTTT
ATTCATTATATTTTTATTTACTTTTTCGAGTTGATCAATTTTTTTATTTTTTAATAAAAGTAAATTATGTT
CACTTTGATTTATGTATTCATTTAAAGTTGAAAAGTTCAAATAATTTCTTGTAGTTATTTCTTTTAAAAGT
ATATTACAATTAGTACATTCATAAGGAGGAAAAGATGTTTTGGAAATTAGCTGTTTGTCTAATATATCCAT
TTCATTTATT 
 
Appendix II.  Binding regions of primers for the mtDNAP 5’ and 3’ homology 
regions cloned into the pUF-1 vector, as well as gRNA locations.  Primer binding 
regions are as follows: 5’HR are highlighted in yellow, 3’HR highlighted in blue, 
flanking primers highlighted in green, and entire insert regions highlighted in grey.  
Guide RNAs are highlighted in purple. 
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CLUSTAL O(1.2.4) multiple sequence alignment 
      
H. sapiens      ------------------------------------------------------------ 
P. falciparum   MKLFDSFFKHALIRINKRNIIYLNATRYYCNNINYNALINLLNKKNDINKEINALYSLLE 
                                                                             
 
H. sapiens      ------------------------------------------------------------ 
P. falciparum   RLSNYKYKQYKDKLTLKNNINDEIKITNADKINNINIERDMNISHLDHHHNNHHHNNNHH 
                                                                             
 
H. sapiens      ----------------------------------------------MSRLLWRKV----- 
P. falciparum   NINHNNHHHNNHHNINHHNNHHNNHHNNNHFNDYKKLIDNWKNDKIKIFISWCPEIVEDK 
                                                                 : *         
 
H. sapiens      ------------------AGATVGP----GPVPAPGRWVSSSVPASDP-----SDGQRRR 
P. falciparum   YKSKCFSIPTYITFHIVITNNDIKLNNLLHNSHEYDDWNFNKIIQTINNQNNLKDKEKEK 
                                  :.  :            . *  ..:  :       .* ::.: 
 
H. sapiens      QQQQQQQQQQ-----QQQPQQPQ------VL--SSEGGQLRHNPLDIQMLSRGLHEQIFG 
P. falciparum   ENGQQHSQEYIGNCKKGESEIPSYDFKESLLEHINESSQLNHS-----ILSHKTKEQTHH 
                :: **:.*:      : : : *.      :*   .*..**.*.     :**:  :** .  
 
H. sapiens      QGGEMPGEAAVRRSVEHLQKHGLWGQ---------------------------------- 
P. falciparum   TNNNINGNYNN---DEHIEEEGKAKTKQNKTKNSIIEEKKKKTKKKKDEESHNDIINYTI 
                 ..:: *:       **:::.*                                       
 
H. sapiens      -------PAVPLPDVELRLPPLYGDNLDQHFRLLAQKQSLPYL--EAANLLLQAQLPPKP 
P. falciparum   KKKTNTNNSLYNIESILNIPKTYEPNIHYDKCIHKEQNHIFFFSFNISELIINDQVKT-- 
                        ::   :  *.:*  *  *:. .  :  ::: : ::  : ::*::: *:     
 
H. sapiens      PAWAWAEGWTRYGPEGEAVPVAIPEERALVFDVEVCLAEGTCPTLAVAISPSAWYSWCSQ 
P. falciparum   -------------------------------KLNECIQQNFIKQNISNIHMDDLFLY--- 
                                               .:: *: :.        *  .  : :    
 
H. sapiens      RLVEERYSWTSQLSPADLIPLE-----------VPT------GASSPTQRDWQEQLVVGH 
P. falciparum   ----VVYDYKNLIHIFNNINLKLININNIFDIYIISSLIQLVQRGEKLQNVYNEYLNVKH 
                      *.:.. :   : * *:           : :        ..  *. ::* * * * 
 
H. sapiens      NVSFDRAH-------IREQYLIQGSRMRFLDTMSMHMAISGLSSFQRSLWIAAKQGKHKV 
P. falciparum   KILIPNKINDIQNLSLHNFSYFSKFAPEFSDVISAKFGLYGWGKYQKKK-----DKKNKK 
                :: : .         :::   :.    .* *.:* ::.: * ..:*:.      : *:*  
 
H. sapiens      QPPTKQGQ---------------------------------------------------- 
P. falciparum   QTENHENNENYENNEYGKNNEYGKNNEYGKNNEYGKNNEYGKNNEYGKNNEYGKNNEYGK 
                *  .::.:                                                     
 
H. sapiens      ----------------------------KSQRKARRGPAISSWDWLDISSVNSLAEVHRL 
P. falciparum   NNVHNDDTYMDISNERKNKKSKEVKNKKKMEKKNKVEKEKQNYLSFTPHNINNLQDIKKL 
                                            * ::* :     ..:  :   .:*.* ::::* 
 
H. sapiens      YVGGPPLEKEPRELFVKGTMKDIRENFQDLMQYCAQDVWATHEVFQQQLPLFLERCPHPV 
P. falciparum   VFGNKR------------NISDITEE--DNICYSISRNC----CLILLFEYFINKLEHNI 
                 .*.              .:.** *:  * : *. .        :   :  *:::  * : 
 
H. sapiens      TLAGMLEMGVSYLPVNQNWERY--------LAEAQGTYEELQREMKKSLMD--LANDAC- 
P. falciparum   NILN------LYIKVEQPLILCISHIEEKGIFLNQNKIEEIQKKSDDPLIYKNEIEELCK 
                .: .       *: *:*             :   *.. **:*:: .. *:     :: *  
 
H. sapiens      -QLLSGERYKEDPWLWDLEWDLQEFKQKKAKKVKKEPATASKLPIEGAGAPGDPMDQEDL 
P. falciparum   CNINLNSSKQVSSLIYKQLLDI---------------------SISTD-HTEENMEDADE 
                 ::  ..  : .  ::.   *:                      *.      : *:: *  
 
H. sapiens      GPCSEEEEFQQDVMARACLQKLKGTTELLPKRPQHLPGHPGWYRKLCPRLDDPAWTPGPS 
P. falciparum   HTDHQEEE-HVNDDNNECVDQLKAYTQTKEKERKDIYN---------------------- 
                    :*** : :   . *:::**. *:   *. :.: .                       
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H. sapiens      LLSLQMRVTPKLMALTWDGFPLHYSERHGWGYLVPGRRDNLAKLPTGTTLESAGVVCPYR 
P. falciparum   ------------------------------------------------------------ 
                                                                             
H. sapiens      AIESLYRKHCLEQGKQQLMPQEAGLAEEFLLTDNSAIWQTVEELDYLEVEAEAKMENLRA 
P. falciparum   -------NNNNENN-------------------------------------KNNNENYN- 
                       ::  *:.                                     : : ** .  
 
H. sapiens      AVPGQPLALTAR---------GGPKDTQPSYHHGNGPYNDVDIPGCWFFKLPHKDGNSCN 
P. falciparum   SSKNHPLITNTNNDDTSTLNAQDTSDQHDNYINEHNNYNKFIKNNPFYYNNNNNNNNNNN 
                :  .:**  .:.          . .* : .* : :. **..   . ::::  :::.*. * 
 
H. sapiens      VGSP-----FAKDFLPKME---DGTLQ-----AGPGG----------------------- 
P. falciparum   NNNDNNNNISNRNLMNNLVNINYTSLYNKKKNSHPYDENNKLFFLNSSHNNYNNNNNNIN 
                 ..        :::: ::      :*      : * .                        
 
H. sapiens      -ASG-----------------------------PRALEINKMISFWRNAHKRISSQMVVW 
P. falciparum   EMSRNKNLQTNNKSLKILVDEIEKSNYIKEKEKEKLKKIIRNIKLYRESKKLVQ-NYIEN 
                  *                               :  :* : *.::*:::* :. : :   
 
H. sapiens      LPRSALPRAVIRHPDYDEEGLYGA----ILPQVVTAGTITRRAV---------------- 
P. falciparum   LPKYIQKNTNKIHCNFNQIGASTGRLSCDQPNLQNIHSRFRCAISLKGKEENDTHDNNNN 
                **:    .:   * :::: *   .      *:: .  :  * *:                 
 
H. sapiens      ----EPTWLTASNARPDRVGSELKAMVQAPPGYTLV-----GADVDSQELWIAAVLGDA- 
P. falciparum   NNNIPQIHISTNNVSTN--NVPMNIMSSTYPLYTMNKKNLITFDYKQMELFVMAYLSFDE 
                        :::.*.  :  .  :: * .: * **:        * .. **:: * *.    
 
H. sapiens      HFAGMHGCTAFGWMTLQGRKSRGTDLHSKTATTVGISREHAKIFNYGRIYGAGQPFAERL 
P. falciparum   QLLKLLN---YSDVFI-----ETAKVLFNTNDVTNELRRMTKTVIYGILYGQTENGLAKS 
                ::  : .   :. : :     . :.:  :*  ...  *. :* . ** :**  :    :  
 
H. sapiens      LMQFNHRLTQQEAAEKAQQMYAATKGLRWYRLSDEGEWLVRELNLPVDRTEGGWISLQDL 
P. falciparum   LLISD-TLAS-NLIENFFQFF-----PNVYRFMQMQKFLVKHMNCVYTLIGRKRIILPNI 
                *:  :  *:. :  *:  *::      . **: :  ::**:.:*          * * :: 
 
H. sapiens      RKVQRETARKSQWKKWEVVAERAWKGGTESEMFNKLESIATSDIPRTPVLGCCISRALEP 
P. falciparum   KN------------KYRI-------------------------SMNTPIQGCAADIM-KF 
                ::            *:.:                           .**: **. .   :  
 
H. sapiens      SAVQEEFMTSRVNWVVQSS--AVDYLHLMLVAMKWLFEEFAIDGRFCISIHD-------- 
P. falciparum   SLL-SCFSVLNNNIYNNNKLLKMNNINPLIIH---KNQAFLNPTNLILQVHDELLLESEH 
                * : . * . . *   :..   :: :: :::      : *    .: :.:**         
 
H. sapiens      -EVRYLVREEDRYRAAL---ALQITNLLTRCMFAYKLGLNDLPQSVAFFSAVDIDRCLRK 
P. falciparum   DATKYIIQLLNPILENAFYNLIYYTNSIDRLKLLYDYMH----DNISIKTYIDILQDINN 
                  .:*:::  :          :  ** : *  : *.       :.::: : :** : :.: 
 
H. sapiens      EVTMDCKTPSNPTGMERRYGIPQGEALDIYQII----------------ELTKGSLEKRS 
P. falciparum   KQYNDV------KLYNGVYNTNVSEESHIYNISNNVDHIFQKFNFKLPIKVESGGVYKES 
                :   *       .  :  *.   .*  .**:*                 :: .*.: *.* 
 
H. sapiens      QPGP 
P. falciparum   S--- 
                .    
  
Appendix III.  Protein sequence alignment of H. sapiens DNA polymerase subunit 
gamma-1 UniProtKB - P54098) and P. falciparum DNA polymerase 1 
(PF3D7_0625300).  Created by Clustal Omega multiple sequence alignment 
software.  
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